Company Overview: TapImmune

Industry News

10 Dec

TapImmune Presents New Data at San Antonio Breast Cancer Symposium Showing Robust Generation of T-Cell Immunity

JACKSONVILLE, Florida, December 10, 2015 /PRNewswire/ — Vaccination with TPIV 100 boosts T-cell immunity to HER2 in HER2+ Breast Cancer Patients Provides catalyst to start Phase II studies TapImmune, Inc. (TPIV), a clinical-stage onco-immunology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer &...

Read more

9 Dec

U.S. Food & Drug Administration Grants Orphan Drug Designation to TapImmune’s TPIV 200 in the Treatment of Ovarian Cancer

Company preparing for Phase II ovarian cancer trial based on positive data in Mayo Clinic Phase I trial JACKSONVILLE, Florida, December 9, 2015 /PRNewswire/ —  TapImmune, Inc. (TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer &...

Read more

7 Dec

TapImmune to Present New Data at San Antonio Breast Cancer Symposium on December 10, 2015

JACKSONVILLE, Florida, December 7, 2015 /PRNewswire/ — TapImmune, Inc. (TPIV), a clinical-stage onco-immunology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced its Chairman and CEO, Dr. Glynn Wilson, will be presenting new data at the 2015...

Read more

30 Nov

TapImmune to Present at LD Micro Main Event on December 1, 2015

JACKSONVILLE, Florida, November 30, 2015 /PRNewswire/ — TapImmune, Inc. (TPIV), a clinical-stage onco-immunology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at the 8th Annual LD Micro Main Event on December 1,...

Read more

5 Nov

Immuno-Oncology Company, TapImmune Inc., Moves Corporate Headquarters to Jacksonville Florida

Clinical-Stage Developer of Vaccines for Cancer & Metastatic Disease moves into closer proximity to collaborators at Mayo Clinic in Jacksonville JACKSONVILLE, Florida, November 5, 2015 /PRNewswire/ —  TapImmune Inc., (TPIV) a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment...

Read more

13 Oct

TapImmune to Present at Dawson James Small Cap Growth Conference in Florida on October 15, 2015

JACKSONVILLE, Florida, October 13, 2015 /PRNewswire/ — TapImmune, Inc.(TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be a featured presenting company at the Dawson James Small Cap Growth Conference at the Wyndham Grand Hotel...

Read more

16 Sep

TapImmune To Provide Update On and Confirmation Of Phase II Clinic Trial Initiation

SEATTLE, Sept. 10, 2015 /PRNewswire/ — TapImmune, Inc. (TPIV), a clinical stage cancer immunotherapy company will hold a conference call on Wednesday, September 16 at 11:00 AM EDT to discuss recent progress in its clinical programs and financing. Following recent announcements on TapImmune signing an exclusive licensing agreement with the Mayo...

Read more

15 Sep

TapImmune Vaccine to be Studied in a $13.3 Million U.S. Department of Defense Grant to Mayo Clinic for Phase II Clinical Trial in Triple Negative Breast Cancer

JACKSONVILLE, Florida, September 15, 2015 /PRNewswire/ — TapImmune, Inc. (TPIV), congratulates Mayo Clinic for being awarded a grant of $13.3 million from the U.S. Department of Defense. This grant, commencing September 15, 2015, will cover the costs for a 280 patient Phase II Clinical Trial of Folate Receptor Alpha Vaccine in...

Read more

8 Sep

TapImmune Inc to Present at the SeeThruEquities Fall MicroCap Investors Conference on September 10, 2015

  JACKSONVILLE, Fla., Sept. 8, 2015 /PRNewswire/ — TapImmune, Inc. (OTCQB: TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be featured as a presenting company at the SeeThruEquity Fall MicroCap Investor Conference....

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address